SignalXSignalX

MNKD MANNKIND CORP

Q3 2025 10-Q
Filed: Nov 5, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
MANNKIND CORP Overview

MANNKIND CORP (MNKD) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

  • • Revenue $82.1M for Q3 FY25, up 17% YoY from $70.1M; Nine months revenue $237.0M, up 14% YoY from $208.7M
  • • Commercial product gross margin 80% Q3 FY25 vs 84% in Q3 FY24; Nine months margin 80% vs 79% YoY
+3 more insights

Risk Factors

  • • New risk: Acquisition-related integration risk triggered by October 2025 scPharma purchase, including increased interest expense and potential net debt impact
  • • Updated operational risk: Manufacturing complications and supply chain challenges intensified by tariffs and U.S.-China trade tensions affecting V-Go production
+3 more insights

Get deeper insights on MANNKIND CORP

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.